A new study appearing in STEM CELLS Translational Medicine demonstrates the promise of a type of cell found in the placenta in helping those suffering from painful and life-threatening severe acute graft-versus-host disease (GvHD). GvHD occurs in up to 70 percent of patients who have undergone a stem cell transplant to treat a disease such as leukemia, using cells other than their own. GvHD develops because the donor's immune cells attack the patient's normal cells.
You are here
Press Releases from AlphaMed Press
A new study appearing in STEM CELLS Translational Medicine (SCTM) shows how understanding the way a type of molecule called CD133 functions might contribute to an understanding of the mechanisms involved in kidney repair.
Kidney injuries affect up to 7 percent of hospitalized patients, with those in intensive care especially vulnerable. An increasing amount of evidence indicates that although the kidney might seem to regain normal function, in fact it remains permanently damaged.
Studies conducted on mice have shown that stem cell therapy is a possible path to total kidney repair. That's why scientists are interested in the CD133 molecule.
STEM CELLS Translational Medicine (SCTM) named Philippe Lysy, M.D., Ph.D., the STEM CELLS Translational Medicine’s Young Investigator of 2017 for his exploration of new sources of cells capable of conversion into insulin-secretors. The award fosters advancements in the field of stem cells and regenerative medicine by honoring a young researcher who is principle author of an article published in SCTM that is deemed to have the most impact and to push the boundaries of novel and insightful research.
In a new study published in STEM CELLS Translational Medicine, researchers used a type of platelet-derived growth factor called PDGF-BB that enhances cells’ ability to regenerate dentin-pulp complex.
Many in the medical community view stem cell therapy as a promising new strategy for repairing teeth once thought to be irreversibly damaged by tooth decay or dental injuries. The benefits of human dental pulp stem cells (hDPSCs), isolated from the living connective tissue in the tooth’s center, on such damage have been well documented in studies.
DURHAM, NC - Each year in the United States more than 300,000 people are hospitalized for hip fractures. Almost half never recover well enough to live an independent lifestyle and, even worse, the one-year mortality rate is high, ranging from 12 percent to 37 percent.
A new review is the first to directly examine the role of various stem cells in the healing of wounded cornea, the outermost part of the eye. In contrast with most other reviews, it covers all major corneal cell types in a comprehensive way, showing similarities and differences in the healing process and the usage of stem cells for therapy.
Corneal wound healing is a complex process that occurs in response to various eye injuries and surgery. Delayed, incomplete, or excessive healing is a significant clinical concern. The review presents evidence on the participation of stem cells in corneal wound healing and highlights how stem cell transplantation may be used to fine tune wound healing and provide benefits for patients.
DURHAM, NC - Studies indicate that replacing damaged brain cells with those derived from human embryonic stem cells might lead to an effective treatment for Parkinson’s disease. But what has not been determined is the optimal stage during differentiation of the stem cells that the transplantation should take place to gain the best results.
DURHAM, NC - A study recently published in STEM CELLS Translational Medicine shows smooth muscle and vascular endothelial cells induced from pluripotent stem cells perform similarly to their naturally evolving counterparts under conditions that mimic hardening of the arteries and other blood vessel diseases. The finding opens the door to modeling rare vascular diseases necessary for research, as well as assists in screening new drugs and developing personalized cell-based therapies.
DURHAM, NC - A new study demonstrates how an infusion of stem cells can assist in treating severe cases of aplastic anemia (AA) that do not respond to immunosuppressive therapy (IST) alone. The study, which appears in STEM CELLS Translational Medicine (SCTM), offers hope for patients with this rare disease, which occurs when the bone marrow does not produce enough blood cells to meet the body’s needs.
DURHAM, NC - AlphaMed Press and the Cord Blood Association (CBA) are pleased to announce that STEM CELLS Translational Medicine (SCTM) is now the association’s official journal. With this partnership, SCTM will launch a new journal section dedicated to cord blood research.
“We are delighted to initiate this partnership with the Cord Blood Association,” said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and Director of the Wake Forest Institute for Regenerative Medicine. “With this new journal section, SCTM further expands the scope of new research reports for our readers – with the potential to accelerate progress in regenerative medicine.”